Aclaris Therapeutics
Develops immunology drug candidates through biologics, kinase inhibitors, and discovery services.
$6.01
After-hours close0.00 (0.00%)
At close$6.01(−2.44%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 85.56%119.49M sharesInsiders 2.30%3.21M sharesOther 12.14%16.96M shares
Shares outstanding 139.66M · Float 113.14M · 81.0% free float
Institutions13F, as of Jun 30, 2026
156 holders · 119.49M shares · 30 new positions · 96 increased · 32 reduced · 15 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Ra Capital Management, L.P. | 12.72M | 9.11% | +5.92M | Aug 14, 2026 |
| BML Capital Management, LLC | 11.98M | 8.57% | −2.28M | Aug 7, 2026 |
| BlackRock, Inc. | 10.04M | 7.19% | +2.63M | Aug 7, 2026 |
| Deep Track Capital, LP | 9.35M | 6.69% | 0 | Aug 14, 2026 |
| Vivo Capital, LLC | 6.69M | 4.79% | +28.0K | Aug 14, 2026 |
| Vanguard Capital Management LLC | 5.82M | 4.17% | +650.4K | Aug 13, 2026 |
| Frazier Life Sciences Management, L.P. | 4.93M | 3.53% | 0 | Aug 14, 2026 |
| Rock Springs Capital Management LP | 4.33M | 3.10% | −142.1K | Aug 14, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| BML Investment Partners, L.P. | 9.90% | 13.95M | 13G | Apr 27, 2026 ↗ |
| Biosion, Inc. | 9.40% | 11.28M | 13G | Jan 9, 2026 ↗ |
| Vivo Opportunity, LLCincl. Vivo Asia Opportunity Fund Holdings, L.P., Vivo Opportunity Cayman, LLC +1 more | 7.40% | 7.96M | 13G | Nov 21, 2024 ↗ |
| Deep Track Capital, LP | 7.00% | 9.35M | 13G | Mar 17, 2026 ↗ |
| RA Capital Management, L.P. | 6.30% | 7.63M | 13G | Apr 7, 2026 ↗ |
| BlackRock, Inc. | 6.20% | 6.70M | 13G | Jan 21, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Leonard Braden Michael | 10 percent owner | 13.95M | 9.99% | Apr 27, 2026 |
| Neal Walker | director, officer: CEO | 1.54M | 1.11% | Feb 5, 2026 |
| Anand Mehra | director | 726.4K | 0.52% | Jun 8, 2026 |
| Joseph Monahan | officer: Chief Scientific Officer | 265.7K | 0.19% | Mar 4, 2025 |
| James Loerop | officer: Chief Business Officer | 192.3K | 0.14% | Feb 5, 2026 |
| Kevin Balthaser | officer: Chief Financial Officer | 187.5K | 0.13% | Mar 3, 2026 |
| Christopher P. Molineaux | director | 69.5K | 0.05% | Jun 8, 2026 |
| Hugh M. Davis | director, officer: President and COO | 45.4K | 0.03% | Feb 5, 2026 |
| William D. Humphries | director | 45.1K | 0.03% | Jun 8, 2026 |
| Maxine Gowen | director | 33.3K | 0.02% | Jun 8, 2026 |
7 ten-percent owners hold 32.03M shares by Form 4, outside the officers-and-directors figure above · 13 people have not refiled in the last 18 months (4.92M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Apr 23, 2026 | Braden Michael Leonard10 percent owner | Sale | 300,000 | $4.53 | 13,950,000 |
CongressHouse and Senate disclosures
Not reported.